Listen to the audio version of this article (generated by AI).
Neuralink is the most talked-about name in brain-computer interfaces, and its ties to Elon Musk make it one of the most-searched names in this sector, especially amid talk of an IPO at a reported $42 billion valuation. There is just one problem: you can’t buy it. Neuralink is still private, so there is no Neuralink stock to purchase yet. The opportunity for everyday investors is in its supply chain, the public companies already building the chips, sensors, and science behind the brain-computer interface boom.
Brain-computer interface (BCI) stocks are shares of public companies working on the technology that lets the brain communicate directly with machines, from the firms building implants to the ones that image and sequence the brain in the first place. Neuralink is the headline act, but it is far from the only player, and it is the one you cannot own.
Can You Buy Neuralink Stock?
Not yet. Neuralink is privately held, so there is no public Neuralink stock and no ticker to buy, and the company has not announced an IPO date. For now, its shares change hands only in private markets open to accredited investors. Everyone else gets exposure to the same trend through the public companies in Neuralink’s orbit.
The Public Neuralink Supply Chain
I laid out this basket back in April 2026, before the Neuralink IPO buzz got loud, and the thesis has been playing out since. You do not have to own Neuralink to invest in brain-computer interfaces. The companies that supply the sequencing, imaging, chips, and implants are public today, and many are still small enough to get in early. The field is filling in fast, with large players pouring in money, the first US pivotal trial for an implanted interface underway, and regulators clearing faster paths to market. Brain mapping is becoming a sequencing problem.
BCI Stocks to Watch Before the Neuralink IPO
Quantum-Si (QSI) is my favorite and a protein-sequencing play on the “sequencing wins” thesis. It is a volatile micro-cap that has surged on recent news and volume. Disclosure: I am personally long QSI and treat it like a call option, sized small.
Butterfly Network (BFLY) makes ultrasound-on-a-chip devices, is further along commercially, and reports earnings in late October.
Hyperfine (HYPR) is a portable-MRI micro-cap on the imaging side, and Nautilus Biotechnology (NAUT) is a proteomics name that has moved with the group.
Medtronic (MDT) is the steady, established medtech option. For the steadiest exposure, the giants behind the science supply what the whole field runs on.
Nvidia (NVDA), Broadcom (AVGO), and Micron (MU) provide the compute and memory, while Thermo Fisher (TMO) and Bruker (BRKR) make the instruments and microscopes.
How to Invest in BCI Stocks Without Getting Burned
These are not blue chips. Most are micro-caps that trade on news and momentum, so treat the smallest names like call options: size each one so losing it all would not hurt, because with a micro-cap that is a real outcome, while the upside can be a multiple of your money. Timing matters too. These stocks move on catalysts, earnings, FDA filings, and the first steps toward approval, and because they rise and fall together, you are buying the theme more than any single winner. A small basket beats one concentrated bet.
Neuralink and BCI Stocks: Frequently Asked Questions
Can you invest in Neuralink?
Not on the public market. Neuralink is private, so retail investors cannot buy its stock yet. Most investors get exposure through public brain-computer interface stocks instead.
When is the Neuralink IPO?
Neuralink has not announced an IPO date and remains private as of 2026, so any timeline is speculation.
What are brain-computer interface (BCI) stocks?
Public companies building the hardware and science behind brain-computer interfaces, from implant makers to imaging and sequencing firms. Examples investors watch include QSI, BFLY, HYPR, and MDT.
The Bottom Line
You can’t buy Neuralink yet, and you don’t have to in order to invest in the brain-computer interface boom. Its supply chain is already public, still small, and still early, which is what makes it both a real opportunity and a real risk. Know what you own, size the micro-caps like the speculative bets they are, and watch the catalysts.
This article is for educational purposes only and is not investment advice. Do your own research before investing.
Jonathan Rose has spent decades as a professional trader. Masters in Trading LIVE is his free class, 15 minutes every market morning at 11 a.m. ET, where he breaks down the setups and sectors he is watching. Sign up for free here.
